MRK•benzinga•
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials
Summary
Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to existing therapies.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga